Novel crystalline form of 3,5-dibromo-N-[(2S)- 2-(-4-fluorophenyl)-4- (3-morpholin-4-ylaztidin-1-yl)butyl]-N-methylbenzamide

Abstract

Two applications separately claim specific crystalline forms of 3,5-dibromo-N-[(2S)-2-(-4-fluorophenyl)-4-(3-morpholin-4-ylazetidin-1-yl)butyl]-N-methylbenzamide, a NK₁/NK₂ antagonist that was first claimed in WO2004110344. The use of the compound for treating a diverse range of disorders, including asthma, gastrointestinal diseases, pain and depression, is claimed.

Keywords::

• crystalline form
• depression
• gastrointestinal disease
• NK₁ antagonist
• NK₂ antagonist
• pain